Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
AmerisourceBergen is a medical distribution business based in the US. AmerisourceBergen shares (ABC) are listed on the NYSE and all prices are listed in US Dollars. AmerisourceBergen employs 39,000 staff and has a trailing 12-month revenue of around $241.8 billion.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $156.79 |
|---|---|
| 52-week range | $133.46 - $174.63 |
| 50-day moving average | $165.59 |
| 200-day moving average | $152.21 |
| Wall St. target price | $183.00 |
| PE ratio | 19.1742 |
| Dividend yield | $1.865 (1.24%) |
| Earnings per share (TTM) | $8.24 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $156.79 from 2023-02-07
| 1 week (2023-02-02) | -1.06% |
|---|---|
| 1 month (2023-01-09) | -4.96% |
| 3 months (2022-11-09) | -0.89% |
| 6 months (2022-08-09) | 8.34% |
| 1 year (2022-02-09) | 9.70% |
|---|---|
| 2 years (2021-02-09) | 47.64% |
| 3 years (2020-02-07) | 76.23% |
| 5 years (2018-02-08) | 85.83% |
Valuing AmerisourceBergen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AmerisourceBergen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AmerisourceBergen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, AmerisourceBergen shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
AmerisourceBergen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5767. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AmerisourceBergen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AmerisourceBergen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.4 billion.
The EBITDA is a measure of a AmerisourceBergen's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $241.8 billion |
|---|---|
| Operating margin TTM | 1.12% |
| Gross profit TTM | $8.3 billion |
| Return on assets TTM | 2.94% |
| Return on equity TTM | 50.2% |
| Profit margin | 0.72% |
| Book value | $-0.88 |
| Market capitalisation | $32 billion |
TTM: trailing 12 months
Dividend payout ratio: 16.95% of net profits
Recently AmerisourceBergen has paid out, on average, around 16.95% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.24% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AmerisourceBergen shareholders could enjoy a 1.24% return on their shares, in the form of dividend payments. In AmerisourceBergen's case, that would currently equate to about $1.865 per share.
While AmerisourceBergen's payout ratio might seem low, this can signify that AmerisourceBergen is investing more in its future growth.
AmerisourceBergen's most recent dividend payout was on 26 February 2023. The latest dividend was paid out to all shareholders who bought their shares by 8 February 2023 (the "ex-dividend date").
AmerisourceBergen's shares were split on a 2:1 basis on 15 June 2009. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AmerisourceBergen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AmerisourceBergen shares which in turn could have impacted AmerisourceBergen's share price.
Over the last 12 months, AmerisourceBergen's shares have ranged in value from as little as $133.4556 up to $174.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AmerisourceBergen's is 0.531. This would suggest that AmerisourceBergen's shares are less volatile than average (for this exchange).
AmerisourceBergen Corporation sources and distributes pharmaceutical products. Its U. S. Healthcare Solutions segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturer. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
